{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,31]],"date-time":"2026-07-31T20:37:18Z","timestamp":1785530238174,"version":"3.56.0"},"reference-count":35,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2024,4,1]],"date-time":"2024-04-01T00:00:00Z","timestamp":1711929600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,4,1]],"date-time":"2024-04-01T00:00:00Z","timestamp":1711929600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,1,8]],"date-time":"2024-01-08T00:00:00Z","timestamp":1704672000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["72074142"],"award-info":[{"award-number":["72074142"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["jhep-reports.eu","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["JHEP Reports"],"published-print":{"date-parts":[[2024,4]]},"DOI":"10.1016\/j.jhepr.2024.101000","type":"journal-article","created":{"date-parts":[[2024,1,11]],"date-time":"2024-01-11T12:32:30Z","timestamp":1704976350000},"page":"101000","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":13,"title":["Universal screening for HCV infection in China: An effectiveness and cost-effectiveness analysis"],"prefix":"10.1016","volume":"6","author":[{"given":"Hua","family":"Zhou","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mengxia","family":"Yan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Datian","family":"Che","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6696-7471","authenticated-orcid":false,"given":"Bin","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jhepr.2024.101000_bib1","doi-asserted-by":"crossref","first-page":"1204","DOI":"10.1016\/S0140-6736(20)30925-9","article-title":"Global burden of 369 diseases and injuries in 204 countries and territories, 1990-2019: a systematic analysis for the Global Burden of Disease Study 2019","volume":"396","year":"2020","journal-title":"Lancet"},{"key":"10.1016\/j.jhepr.2024.101000_bib2","doi-asserted-by":"crossref","first-page":"533","DOI":"10.1038\/s41575-020-0332-6","article-title":"Progress towards elimination goals for viral hepatitis","volume":"17","author":"Cox","year":"2020","journal-title":"Nat Rev Gastroenterol Hepatol"},{"key":"10.1016\/j.jhepr.2024.101000_bib3","article-title":"The disconnect in hepatitis screening: participation rates, awareness of infection status, and treatment-seeking behavior","volume":"9","author":"Lin","year":"2019","journal-title":"J\u00a0Glob Health"},{"key":"10.1016\/j.jhepr.2024.101000_bib4","first-page":"1427","article-title":"Eliminate hepatitis C as a public health threat: a narrative review of strategies, gaps, and opportunities for China","volume":"11","author":"Song","year":"2022","journal-title":"Infect Dis Ther"},{"key":"10.1016\/j.jhepr.2024.101000_bib5","doi-asserted-by":"crossref","first-page":"4436","DOI":"10.3390\/ijerph16224436","article-title":"Hepatitis C virus treatment status and barriers among patients in methadone maintenance treatment clinics in Guangdong Province, China: a cross-sectional, observational study","volume":"16","author":"Liu","year":"2019","journal-title":"Int J Environ Res Public Health"},{"key":"10.1016\/j.jhepr.2024.101000_bib6","first-page":"627","article-title":"Interpretation of the national action plan for eliminating hepatitis C as a public health threat (2021\u20132030)","volume":"4","author":"Li","year":"2022","journal-title":"China CDC Wkly"},{"key":"10.1016\/j.jhepr.2024.101000_bib7","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1016\/j.jval.2021.10.008","article-title":"Consolidated health economic evaluation reporting standards (CHEERS) 2022 explanation and elaboration: a report of the ISPOR CHEERS II good practices task force","volume":"25","author":"Husereau","year":"2022","journal-title":"Value Health"},{"key":"10.1016\/j.jhepr.2024.101000_bib8","doi-asserted-by":"crossref","first-page":"1097","DOI":"10.1080\/17474124.2021.1963231","article-title":"Sofosbuvir\/velpatasvir for the treatment of hepatitis C in pediatric patients","volume":"15","author":"Rubino","year":"2021","journal-title":"Expert Rev Gastroenterol Hepatol"},{"key":"10.1016\/j.jhepr.2024.101000_bib9","doi-asserted-by":"crossref","DOI":"10.1136\/bmjopen-2016-011821","article-title":"Cost-effectiveness of screening for hepatitis C virus: a systematic review of economic evaluations","volume":"6","author":"Coward","year":"2016","journal-title":"BMJ Open"},{"key":"10.1016\/j.jhepr.2024.101000_bib10","doi-asserted-by":"crossref","first-page":"785","DOI":"10.1016\/j.jhep.2018.05.027","article-title":"Assessing the cost-effectiveness of hepatitis C screening strategies in France","volume":"69","author":"Deuffic-Burban","year":"2018","journal-title":"J\u00a0Hepatol"},{"key":"10.1016\/j.jhepr.2024.101000_bib11","doi-asserted-by":"crossref","first-page":"91","DOI":"10.3350\/cmh.2021.0236","article-title":"A\u00a0cost-effectiveness study of universal screening for hepatitis C virus infection in South Korea: a societal perspective","volume":"28","author":"Kim","year":"2021","journal-title":"Clin Mol Hepatol"},{"key":"10.1016\/j.jhepr.2024.101000_bib12","doi-asserted-by":"crossref","first-page":"e59","DOI":"10.1097\/INF.0000000000002717","article-title":"Cost-effectiveness of oral regimens for adolescents with chronic hepatitis C virus infection","volume":"39","author":"Zhou","year":"2020","journal-title":"Pediatr Infect Dis J"},{"key":"10.1016\/j.jhepr.2024.101000_bib13","unstructured":"WHO | Life tables n.d. https:\/\/www.who.int\/gho\/mortality_burden_disease\/life_tables\/life_tables\/en\/ Accessed 22 November\u00a02023."},{"key":"10.1016\/j.jhepr.2024.101000_bib14","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.vhri.2020.07.580","article-title":"Current development and practice of pharmacoeconomic evaluation guidelines for universal health coverage in China","volume":"24","author":"Yue","year":"2021","journal-title":"Value Health Reg Issues"},{"key":"10.1016\/j.jhepr.2024.101000_bib15","doi-asserted-by":"crossref","first-page":"418","DOI":"10.1002\/hep.22375","article-title":"Estimation of stage-specific fibrosis progression rates in chronic hepatitis C virus infection: a meta-analysis and meta-regression","volume":"48","author":"Thein","year":"2008","journal-title":"Hepatology"},{"key":"10.1016\/j.jhepr.2024.101000_bib16","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1001\/jamainternmed.2015.6011","article-title":"Cost-effectiveness of early treatment of hepatitis C virus genotype 1 by stage of liver fibrosis in a US treatment-naive population","volume":"176","author":"Chahal","year":"2016","journal-title":"JAMA Intern Med"},{"key":"10.1016\/j.jhepr.2024.101000_bib17","doi-asserted-by":"crossref","first-page":"821","DOI":"10.1053\/j.gastro.2008.05.044","article-title":"Eradication of hepatitis C virus in patients successfully treated for chronic hepatitis C","volume":"135","author":"Maylin","year":"2008","journal-title":"Gastroenterology"},{"key":"10.1016\/j.jhepr.2024.101000_bib18","doi-asserted-by":"crossref","first-page":"361","DOI":"10.5812\/hepatmon.6095","article-title":"Treatment of patients with HCV related cirrhosis: many rewards with very few risks","volume":"12","author":"D\u2019Ambrosio","year":"2012","journal-title":"Hepat Mon"},{"key":"10.1016\/j.jhepr.2024.101000_bib19","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1016\/S0168-8278(97)80302-9","article-title":"Effectiveness of interferon alfa on incidence of hepatocellular carcinoma and decompensation in cirrhosis type C. European Concerted Action on Viral Hepatitis (EUROHEP)","volume":"27","author":"Fattovich","year":"1997","journal-title":"J\u00a0Hepatol"},{"key":"10.1016\/j.jhepr.2024.101000_bib20","doi-asserted-by":"crossref","first-page":"329","DOI":"10.7326\/0003-4819-158-5-201303050-00005","article-title":"Eradication of hepatitis C virus infection and the development of hepatocellular carcinoma: a meta-analysis of observational studies","volume":"158","author":"Morgan","year":"2013","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.jhepr.2024.101000_bib21","doi-asserted-by":"crossref","first-page":"748","DOI":"10.1002\/lt.22072","article-title":"Timing of hepatitis C antiviral therapy in patients with advanced liver disease: a decision analysis model","volume":"16","author":"Saab","year":"2010","journal-title":"Liver Transpl"},{"key":"10.1016\/j.jhepr.2024.101000_bib22","doi-asserted-by":"crossref","first-page":"605","DOI":"10.1111\/apt.14241","article-title":"Ethnic disparities in progression to advanced liver disease and overall survival in patients with chronic hepatitis C: impact of a sustained virological response","volume":"46","author":"Le","year":"2017","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1016\/j.jhepr.2024.101000_bib23","doi-asserted-by":"crossref","first-page":"1661","DOI":"10.1007\/s40121-022-00666-0","article-title":"Effectiveness and safety of sofosbuvir\/velpatasvir\/voxilaprevir as a hepatitis C virus infection salvage therapy in the real world: a systematic review and meta-analysis","volume":"11","author":"Xie","year":"2022","journal-title":"Infect Dis Ther"},{"key":"10.1016\/j.jhepr.2024.101000_bib24","doi-asserted-by":"crossref","first-page":"6247","DOI":"10.1002\/jmv.27157","article-title":"Real-world clinical outcomes of sofosbuvir and velpatasvir treatment in HCV genotype 1- and 2-infected patients with decompensated cirrhosis: a nationwide multicenter study by the Japanese Red Cross Liver Study Group","volume":"93","author":"Tada","year":"2021","journal-title":"J\u00a0Med Virol"},{"key":"10.1016\/j.jhepr.2024.101000_bib25","doi-asserted-by":"crossref","first-page":"763","DOI":"10.1080\/14787210.2019.1675509","article-title":"How would China achieve WHO\u2019s target of eliminating HCV by 2030?","volume":"17","author":"Li","year":"2019","journal-title":"Expert Rev Anti Infect Ther"},{"key":"10.1016\/j.jhepr.2024.101000_bib26","doi-asserted-by":"crossref","first-page":"263","DOI":"10.7326\/0003-4819-156-4-201202210-00378","article-title":"The cost-effectiveness of birth-cohort screening for hepatitis C antibody in U.S. primary care settings","volume":"156","author":"Rein","year":"2012","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.jhepr.2024.101000_bib27","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0245288","article-title":"Economic and epidemiological evaluation of interventions to reduce the burden of hepatitis C in Yunnan province, China","volume":"16","author":"Heffernan","year":"2021","journal-title":"PLoS One"},{"key":"10.1016\/j.jhepr.2024.101000_bib28","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1016\/j.jval.2019.07.005","article-title":"A\u00a0systematic review and meta-analysis of health utilities in patients with chronic hepatitis C","volume":"23","author":"Saeed","year":"2020","journal-title":"Value Health"},{"key":"10.1016\/j.jhepr.2024.101000_bib29","article-title":"Feasibility of hepatitis C elimination in China: from epidemiology, natural history, and intervention perspectives","volume":"13","author":"Zhao","year":"2022","journal-title":"Front Microbiol"},{"key":"10.1016\/j.jhepr.2024.101000_bib30","doi-asserted-by":"crossref","first-page":"270","DOI":"10.35772\/ghm.2021.01080","article-title":"Prevalence, diagnosis, and treatment of hepatitis C in Mainland China","volume":"3","author":"Mei","year":"2021","journal-title":"Glob Health Med"},{"key":"10.1016\/j.jhepr.2024.101000_bib31","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1007\/s40273-012-0011-8","article-title":"Cost-effectiveness acceptability curves revisited","volume":"31","author":"Al","year":"2013","journal-title":"Pharmacoeconomics"},{"key":"10.1016\/j.jhepr.2024.101000_bib32","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1136\/jech.55.2.123","article-title":"The discount rate in the economic evaluation of prevention: a thought experiment","volume":"55","author":"Bonneux","year":"2001","journal-title":"J\u00a0Epidemiol Community Health"},{"key":"10.1016\/j.jhepr.2024.101000_bib33","doi-asserted-by":"crossref","first-page":"1255","DOI":"10.3390\/diagnostics12051255","article-title":"Diagnostic accuracy of point-of-care HCV viral load assays for HCV diagnosis: a systematic review and meta-analysis","volume":"12","author":"Tang","year":"2022","journal-title":"Diagnostics (Basel)"},{"key":"10.1016\/j.jhepr.2024.101000_bib34","doi-asserted-by":"crossref","first-page":"683","DOI":"10.1093\/cid\/civ948","article-title":"Risk of late relapse or reinfection with hepatitis C virus after achieving a sustained virological response: a systematic review and meta-analysis","volume":"62","author":"Simmons","year":"2016","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.jhepr.2024.101000_bib35","doi-asserted-by":"crossref","first-page":"371","DOI":"10.1016\/j.jhep.2018.11.013","article-title":"Epidemiology and natural history of hepatitis C virus infection among children and young people","volume":"70","author":"Modin","year":"2019","journal-title":"J\u00a0Hepatol"}],"container-title":["JHEP Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2589555924000016?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2589555924000016?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,11]],"date-time":"2025-11-11T22:33:16Z","timestamp":1762900396000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2589555924000016"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,4]]},"references-count":35,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2024,4]]}},"alternative-id":["S2589555924000016"],"URL":"https:\/\/doi.org\/10.1016\/j.jhepr.2024.101000","relation":{},"ISSN":["2589-5559"],"issn-type":[{"value":"2589-5559","type":"print"}],"subject":[],"published":{"date-parts":[[2024,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Universal screening for HCV infection in China: An effectiveness and cost-effectiveness analysis","name":"articletitle","label":"Article Title"},{"value":"JHEP Reports","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jhepr.2024.101000","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 The Author(s). Published by Elsevier B.V. on behalf of European Association for the Study of the Liver (EASL).","name":"copyright","label":"Copyright"}],"article-number":"101000"}}